Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.252 USD | -23.64% | -11.89% | -87.71% |
15/04 | Ampio Pharmaceuticals, Inc.(NYSEAM:AMPE) dropped from S&P TMI Index | CI |
27/03 | Ampio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 42.13 | 92.49 | 294.2 | 129.5 | 3.397 | 1.706 |
Enterprise Value (EV) 1 | 34.55 | 87.43 | 277.8 | 95.61 | -8.487 | -1.966 |
P/E ratio | 1.29 x | -4.13 x | -17.3 x | -5.68 x | -0.15 x | -0.19 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -3.49 x | -5.05 x | -19 x | -4.91 x | 0.44 x | 0.21 x |
EV / FCF | -4.09 x | -10.5 x | -27.7 x | -17.2 x | 0.6 x | 0.37 x |
FCF Yield | -24.4% | -9.54% | -3.62% | -5.83% | 167% | 273% |
Price to Book | 8.36 x | 14.4 x | 17.6 x | 4.75 x | 0.29 x | 0.51 x |
Nbr of stocks (in thousands) | 356 | 529 | 617 | 757 | 754 | 832 |
Reference price 2 | 118.4 | 174.9 | 477.0 | 171.0 | 4.504 | 2.050 |
Announcement Date | 18/03/19 | 21/02/20 | 03/03/21 | 29/03/22 | 27/03/23 | 27/03/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -9.903 | -17.3 | -14.66 | -19.48 | -19.33 | -9.391 |
EBIT 1 | -11.18 | -18.58 | -15.83 | -20.57 | -20.38 | -9.518 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | 33.99 | -13.63 | -15.89 | -17.08 | -16.34 | -8.632 |
Net income 1 | 33.99 | -13.63 | -15.89 | -17.08 | -16.34 | -8.632 |
Net margin | - | - | - | - | - | - |
EPS 2 | 91.90 | -42.32 | -27.59 | -30.10 | -29.32 | -10.66 |
Free Cash Flow 1 | -8.446 | -8.34 | -10.05 | -5.575 | -14.16 | -5.372 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 18/03/19 | 21/02/20 | 03/03/21 | 29/03/22 | 27/03/23 | 27/03/24 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 |
---|---|---|---|---|
Net sales 1 | - | - | - | - |
EBITDA | - | - | - | - |
EBIT 1 | -3.851 | -9.228 | -6.97 | -4.988 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | -3.628 | -6.224 | -5.636 | -2.07 |
Net income 1 | -3.628 | -6.224 | -5.636 | -2.07 |
Net margin | - | - | - | - |
EPS 2 | -6.000 | -12.00 | -6.000 | -3.000 |
Dividend per Share | - | - | - | - |
Announcement Date | 10/11/21 | 29/03/22 | 16/05/22 | 09/08/22 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 7.59 | 5.06 | 16.4 | 33.9 | 11.9 | 3.67 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -8.45 | -8.34 | -10 | -5.57 | -14.2 | -5.37 |
ROE (net income / shareholders' equity) | -235% | -233% | -133% | -76.2% | -83.6% | -114% |
ROA (Net income/ Total Assets) | -47.6% | -82.8% | -53.7% | -41.7% | -48.6% | -61.6% |
Assets 1 | -71.34 | 16.45 | 29.62 | 40.97 | 33.61 | 14.02 |
Book Value Per Share 2 | 14.20 | 12.20 | 27.20 | 36.00 | 15.60 | 4.030 |
Cash Flow per Share 2 | 20.50 | 12.40 | 26.90 | 44.70 | 16.80 | 4.910 |
Capex 1 | 0.56 | 0.02 | 0.06 | 0.1 | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 18/03/19 | 21/02/20 | 03/03/21 | 29/03/22 | 27/03/23 | 27/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-87.71% | 375K | |
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |
- Stock Market
- Equities
- AMPE Stock
- Financials Ampio Pharmaceuticals, Inc.